Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled GSK2269557 for acute exacerbation of COPD
2015-003696-30Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing GSK2269557 with Placebo (2 arms). Primary endpoint: Neutrophil-related sputum mRNA transcriptomic changes. Started Jan 2016; status: completed.
02
Drugs
nemiralisib
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2015-003696-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003696-30.